Status:
COMPLETED
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults
Lead Sponsor:
GlaxoSmithKline
Collaborating Sponsors:
Corixa Corporation
Conditions:
Tuberculosis (TB)
Eligibility:
All Genders
18-40 years
Phase:
PHASE1
Brief Summary
This Phase I study will evaluate the safety and immunogenicity of two doses GSK Biologicals' candidate TB vaccine (692342) according to a 0, 1, 2 months schedule in PPD-negative adults.
Eligibility Criteria
Inclusion
- Healthy male or female between 18 and 40 years of age at the time of screening
- Negative PPD skin test at screening.
- Subjects must have chest X-ray showing no evidence of pulmonary pathology.
- Female subjects of childbearing potential must have a negative serum pregnancy test at screening, must not be breast-feeding and are required to use adequate contraception from enrolment till 1 month after dose 3.
- Screening laboratory values must be within the laboratory normal ranges.
- Negative for human immunodeficiency virus-1 and 2 (HIV 1/2) antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody.
- Subjects must give written informed consent.
- Subjects must be willing to make all evaluation visits, be readily reachable by telephone or personal contact by the study site personnel and have a permanent address.
- Subjects' resting seated vital signs must be within the protocol-defined ranges.
Exclusion
- History of prior Bacillus Calmette-Guérin (BCG) vaccinations.
- History of documented exposure to Mycobacterium tuberculosis.
- History of previous administration of experimental Mycobacterium tuberculosis vaccines or previous exposure to experimental products containing components of the experimental vaccine.
- History of employment in a healthcare facility in a capacity that had direct or indirect contact with TB patients.
- Administration of any immunoglobulins or any immunotherapy within the 3 months preceding the first dose of study vaccination, and/or any blood products within the 4 months preceding HIV screening, or planned administrations during the study period.
- Use of St. John's Wort within six months of the Day 0 visit or planned administrations during the study period.
- Participation in another experimental protocol and/or receipt of any investigational products within 30 days prior to Day 0.
- History of autoimmune disease or causes of immunosuppressive states.
- History of any acute or chronic illness or medication that, in the opinion of the Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.
- History of significant psychiatric illness.
- Current drug or alcohol abuse
- History of previous anaphylaxis or severe allergic reaction to vaccines or any other allergen.
- Subjects who are, in the opinion of the investigator, at significantly increased risk of non-cooperation with requirements of the study protocol.
- Any chronic drug therapy to be continued during the study period, with the exception of vitamins and/or dietary supplements (including mineral preparations such as calcium carbonate), herbal medications except St. John's Wort, birth control pills, anti-histamines for seasonal allergies, SSRIs (e.g. Prozac, Zoloft, Paxil), NSAIDs (e.g. aspirin, ibuprofen), and acetominophen.
- Chronic administration (defined as more than 14 days total) of immunosuppressants or other immune modifying drugs within six months prior to the first vaccine dose.
- History of chronic or intermittently recurring illnesses such as migraine headaches, diabetes, heart disease, and asthma.
- Current administration of anti-TB prophylaxis or therapy.
- History of administration of a live attenuated virus vaccine within 30 days of enrollment.
- History of administration of a subunit or killed vaccine within 14 days of enrollment.
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00730795
Start Date
January 1 2004
Last Update
August 8 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Clinical Trials Call Center
Tacoma, Washington, United States, 9843